Simon Fletcher is a Vice President at Gilead Sciences, where he leads a group focused on developing novel therapies for acute and chronic viral infections.
Conflict of interest: Dr Fletcher receives a salary from Gilead Sciences, and also holds intellectual property rights/patent, and has an ownership interest with them.